Rapport Therapeutics Company Insiders

Rapport Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (0.1589) % which means that it has lost $0.1589 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2341) %, meaning that it created substantial loss on money invested by shareholders. Rapport Therapeutics' management efficiency ratios could be used to measure how well Rapport Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 01/02/2026, Return On Tangible Assets is likely to drop to -0.23. In addition to that, Return On Capital Employed is likely to drop to -0.26. As of 01/02/2026, Total Current Liabilities is likely to drop to about 7.1 M. In addition to that, Liabilities And Stockholders Equity is likely to drop to about 184.1 MAs of 01/02/2026, Common Stock Shares Outstanding is likely to drop to about 216.1 MThe majority of Rapport Therapeutics Common outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Rapport Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Rapport Therapeutics. Please pay attention to any change in the institutional holdings of Rapport Therapeutics as this could imply that something significant has changed or is about to change at the company. As of 01/02/2026, Dividend Paid And Capex Coverage Ratio is likely to drop to -32.55. As of 01/02/2026, Common Stock Shares Outstanding is likely to drop to about 216.1 M.

Rapport Therapeutics Workforce Comparison

Rapport Therapeutics Insider Trading

Rapport Therapeutics Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as Rapport Therapeutics often depends on how effective the management is. Rapport Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Rapport management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Rapport management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

When running Rapport Therapeutics' price analysis, check to measure Rapport Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rapport Therapeutics is operating at the current time. Most of Rapport Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rapport Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rapport Therapeutics' price. Additionally, you may evaluate how the addition of Rapport Therapeutics to your portfolios can decrease your overall portfolio volatility.